NASDAQ:CYTK
Cytokinetics Stock News
$67.55
+0.550 (+0.82%)
At Close: Apr 19, 2024
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
09:27am, Wednesday, 10'th Apr 2024
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
7 Biotech Stocks Ready to Ride the Sector's Resurgence
08:01pm, Monday, 18'th Mar 2024
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
Cytokinetics: CEO Talks Down Buyout Prospects
03:43am, Saturday, 16'th Mar 2024
Cytokinetics: CEO Talks Down Buyout Prospects
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
02:25pm, Wednesday, 13'th Mar 2024
While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as inno
Cytokinetics to Participate in March Investor Conferences
04:00pm, Monday, 04'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor confere
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
06:11pm, Tuesday, 27'th Feb 2024
Cytokinetics (CYTK) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to loss of $1.45 per share a year ago.
Cytokinetics to Announce Fourth Quarter Results on February 27, 2024
04:00pm, Tuesday, 13'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
09:10am, Thursday, 08'th Feb 2024
The technology applied in the field of medicine undoubtedly surprises more and more investors every day. As technology advances in the world, biotech companies are in charge of applying it to improve
Cytokinetics (CYTK) Down on Report of Novartis Not Interested
04:32pm, Friday, 12'th Jan 2024
Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.
Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)
11:54pm, Thursday, 11'th Jan 2024
Previously recommended "Sell" on Cytokinetics; Aficamten's SEQUOIA-HCM data outperformed expectations, necessitating reevaluation. Aficamten revealed possibly improved efficacy and safety compared to
Cytokinetics stock plunges as Novartis retreats from merger talks
05:37pm, Thursday, 11'th Jan 2024
Cytokinetics stock plunged more than 16% Thursday to $84.95 after talks reportedly broke down with potential potential buyer Novartis AG (ADR) (NYSE:NVS). Shares of the biopharmaceutical company hav
Novartis Pursuit of Cytokinetics Cools
12:19pm, Thursday, 11'th Jan 2024
Novartis has backed away from its pursuit of Cytokinetics.
Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis
03:02pm, Tuesday, 09'th Jan 2024
Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.
Novartis in advanced talks to buy Cytokinetics
03:29pm, Monday, 08'th Jan 2024
Cytokinetics Inc (NASDAQ: CYTK) popped another 15% on Monday following a report that Novartis AG (SWX: NOVN) is now in advanced talks to acquire the biopharmaceutical firm.
Novartis, Cytokinetics near merger: report
01:25pm, Monday, 08'th Jan 2024
Novartis NOVN, +0.43% is close to acquiring Cytokinetics Inc. CYTK, +15.04% and its promising heart drug, according to a Wall Street Journal report Monday. A deal for South San Francisco-based Cytokin